

Corporate Overview – October 2019

Joseph Oliveto Chief Executive Officer

Disclaimers



This Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include. but are not limited to, statements about the initiation, timing, progress and results of our current and future clinical trials of etripamil, including our Phase 3 clinical trials of etripamil for the treatment of paroxysmal supraventricular tachycardia ("PSVT"), and of our research and development programs and clinical pipeline; our plans to develop and commercialize etripamil and any future product candidates; the expected benefits of using etripamil to treat PSVT; our expectations regarding the potential market size and the rate and degree of market acceptance of etripamil and any future product candidates and the implementation of our business model and strategic plans for our business, etripamil and any future product candidates. Such forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our dependence on the success of our Phase 3 clinical trials of etripamil for PSVT, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation, enrollment and completion of clinical trials, and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others. These and other risks and uncertainties are described more fully in our annual and other periodic filings with the Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC on August 13, 2019. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise.

This Presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Certain information contained in this Presentation and statements made orally during this Presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the Presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of the Company's internal estimates or research and no reliance should be made on any information or statements made in this Presentation relating to or based on such internal estimates and research.

Milestone - Corporate Highlights



- Phase 3 Cardiovascular Company with data read out anticipated in 1H, 2020
- PSVT is a robust market represented by ~2M patients in US
- Paradigm-changing approach enabling patient self-management
- Potentially first new drug therapy in PSVT in > 25 years
- New Chemical Entity with proprietary IP protection until 2036
- Pipeline opportunities beyond the lead indication
- \$95M Initial Public Offering May 13, 2019
- Cash and equivalents of \$145.8M (June 30, 2019) expected runway into Q3, 2021


Management Team






Paroxysmal Supraventricular Tachycardia (PSVT)





PSVT episode frequency (per yr.)



- PSVT is a rapid heart rate condition that starts and stops without warning
- Heart rates >200 bpm are not uncommon
- Symptoms include
 - ✓ palpitations
 - ✓ sweating
 - chest pressure or pain, shortness of breath
 - ✓ sudden onset of fatigue
 - ✓ lightheadedness or dizziness
 - fainting or anxiety

AVNRT = Atrioventricular Nodal Re-entrant Tachycardia AVRT = Atrioventricular Re-entrant Tachycardia bpm = beats per minute

Current Standard of Care for PSVT



Current acute treatment options are invasive, inconvenient, anxiety-provoking and/or costly



Chronic / preventive

- Chronic oral medication with modest efficacy and unpleasant side effects
- 4-7 episodes/year despite preventive medications



- Catheter ablation
- ~80K ablations/year
- Only ~10% of patients opt for ablation



- IV adenosine or DC cardioversion in the ED
- >150K ED visits/hospital admissions per year
- Many patients endure episodes when they occur


PSVT = Paroxysmal Supraventricular Tachycardia DC = Direct Current ED = Emergency Department

Sources: Internal estimates based on market research and longitudinal analysis of Truven/Marketscan and Medicare claims data; Page RL et al, 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the ACC/AHA Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133:e471–e505

A Paradigm-Changing Approach



Opportunity to develop the first approved treatment to be used by patients whenever and wherever an episode of PSVT occurs



- Avoidance of ED visits/ hospital admissions
- Less need for chronic medications
- Alternative or bridge to ablation procedure



Potential Commercial Opportunity for Etripamil in PSVT



~2M diagnosed PSVT patients (4 yr. prevalence)	800,000 TAM (40% of 2M)	400,000 Etripamil patients (50% of TAM)
---	-----------------------------------	---

Number of annual PSVT ablations	80,000
Ratio of etripamil-treated patients : ablation	x <u>3.5</u>
Total expected etripamil patients/year	280,000
Etripamil expected doses/patient/year	x <u>3</u>
Etripamil doses/year	840,000

TAM – Target Addressable Market

Sources: Internal estimates based on market research and longitudinal analysis of Truven/Marketscan and Medicare claims data

Etripamil




A paradigm-changing approach for treating PSVT

	Etripamil		
Class	Novel CCB		
Potency (IC ₅₀)	11 nM		
Metabolism	Rapid: Esterase-mediated		

- Clinically-validated mechanism
 - Etripamil, Calcium Channel Blockers (CCBs), terminate PSVT through AV node modulation
- Rapid onset of action
- Convenient patient self-administered nasal spray
- Short half-life

- Rapid onset (T_{max} < 5 min)
- Transient plasma levels



Error bars indicate standard error of the mean

Etripamil Clinical Pipeline




Pharmacology of L-type calcium channel blockers drives broad clinical utility

	Preclinical	Phase 1	Phase 2	Phase 3
PSVT	Rapid con	version to si	nus rhythm	
Atrial Fibrillation	Temporary rapid ventri			
Angina	Acute relief sympt			


Etripamil PSVT Phase 3 Development Plan





Phase 2a/b Study Design






Endpoint: conversion to sinus rhythm within 15 minutes >80% power to show a 50% absolute difference vs. placebo

EP = electrophysiology, SVT = supraventricular tachycardia, PSVT = Paroxysmal Supraventricular Tachycardia

Phase 2 Primary Endpoint




Etripamil three highest doses demonstrated 75-95% conversion rates which are statistically significant compared to placebo



Source: Stambler, B.S. et al.; Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm; J Am Coll Cardiol. 2018;72(5):489–97

Phase 2 Time to Conversion






Time Since Study Drug Administration (min)

*Hazard Ratio and 95% Confidence Intervals etripamil 70mg vs. placebo; 4.99 (2.09, 11.93)

Source: Stambler, B.S. et al.; Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm; J Am Coll Cardiol. 2018;72(5):489–97

Phase 2 Mean Systolic Blood Pressure Effects





measurements during supraventricular tachycardia between 5 and 0 min before study drug administration. *p < 0.05 versus baseline.

Source: Stambler, B.S. et al.; Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm; J Am Coll Cardiol. 2018;72(5):489–97

Phase 2a/b Clinical Conclusions




- Etripamil at 70, 105 and 140 mg is significantly better than placebo in terminating PSVT
- Median time to conversion <3 min with etripamil 70mg
- 70 mg dose showed no mean blood pressure (BP) drop
- Most frequent side effect was nasal irritation or nasal congestion; however these were transient
- Etripamil 70 mg demonstrated the best efficacy/safety profile to take into Phase 3

Source: Adapted from Stambler, B.S. et al.; Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm; J Am Coll Cardiol. 2018;72(5):489–97

Pivotal Phase 3 Study Design



Objective: Superiority of etripamil over placebo in terminating PSVT events in the outpatient setting



SR = Sinus Rhythm; PSVT = Paroxysmal Supraventricular Tachycardia; Study randomization scheme 2:1 etripamil : placebo



NODE-301

Single pivotal efficacy study to support NDA submission

• Once target of 150 adjudicated events reached, collection of blinded data from patients who have not experienced an event to continue as separate dataset called "NODE-301B"

NODE-303

Open-label global safety trial


• Removed the in-office safety test dose that is currently required in the NODE-301 study

Population and Safety Database

- Program enrolling broad patient population including elderly and those on concomitant medications (e.g. calcium channel blockers and beta blockers)
- Total NDA safety data set of ≤ 1,500 unique patient events

Etripamil PSVT Phase 3 Development Plan






Milestone Knowledge Base for PSVT



Market research with extensive stakeholder interviews supplemented with multiple claims database analyses



PSVT Patient Characteristics

- Age: teens to elderly
- Gender: majority are female
- Episode frequency and duration varies widely
 - Median 4-7 per year despite chronic medications
 - Almost 40% of patients have at least 2 episodes/year >10 min*
- Cardiovascular comorbidities in about half of patients
- 40% of patients have ≥ 1 ED visit per year*



Unmet Need

- Strongly negative experience associated with **adenosine in ED**
- Significant anxiety/fear of **ablation**
- Patients indicate
 "significant impact"
 on QOL


*Estimates are for patients in year after initial diagnosis; rates drop by 13-29% in years following their initial diagnosis Sources: Internal estimates based on market research and longitudinal analysis of Truven/Marketscan and Medicare claims data

Current US PSVT Market



Total annual US healthcare expenditures of ~\$3B


- Prevalence ~2M diagnosed PSVT patients
- ~300K newly diagnosed per year
- ~600K patients treated per year
- >150K ED/hospital visits per year
- ~80K ablations per year



Source: Sacks, N.C. et al; Prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) in the US in Patients Under 65 Years of Age; Abstract and Oral Presentation at the International Academy of Cardiology Annual Scientific Sessions 2018, 23rd World Congress on Heart Disease; Precision Xtract, Boston, MA, USA; and data-on-file from Truven Health MarketScan Commercial research database and Medicare Limited Dataset, with demographic, enrollment and claims data for commercially insured (Truven) and Medicare covered patients using PSVT code 427.0 or I47.1 for up to a 9-year interval between 2008 and 2016 inclusive.

Target Addressable Market for PSVT






TAM – Target Addressable Market

*Estimates are for patients in year after initial diagnosis; rates drop by 13-29% in years following their initial diagnosis

Sources: Internal estimates based on market research

Etripamil – Addressing Market Needs





Cards = Cardiologists, EPs = Electrophysiologists, PCPs = Primary Care Physicians

Sources: Internal market research

PSVT Patient Management and Call Point Targeting



Majority of PSVT patients managed by CV specialists, leading to commercial efficiencies

		Clinical Cardiologists	Primary Care Physicians	Electro- physiologists	
% of PSVT patients managed		~60%	~30%	~10%	
Long-term Use	Add to or Replace Chronic Medications	Primary Target			
Medium-term Use	Defer Ablation			Secondary	
Short-term Use	Bridge to Ablation			Target	

- Targeted sales force to reach majority of available opportunity
- Significant overlap with most common CV portfolio call points

Source: Internal market research


Finances



- Cash and equivalents of \$145.8M (as of June 30, 2019)
 - IPO (May 2019) net proceeds of approx. \$86M
- Runway expected into Q3, 2021
 - Phase 3 pivotal efficacy trial (NODE-301) top line data
 - Significant progression of Phase 3 safety study (NODE-303)
 - Continued PSVT market development via publications, patient education and Medical Affairs initiatives
 - Phase 2 endpoint in atrial fibrillation
- 24.5M shares outstanding

Etripamil Development Plan





Milestone (Nasdaq: MIST) - Corporate Highlights



- Phase 3 Cardiovascular Company with pivotal efficacy data in 1H 2020
- PSVT is a robust market represented by ~2M patients in US
- Potentially first new drug therapy in PSVT in > 25 years
- Paradigm-changing approach enabling patient self-management & potential cost savings to the medical system
- Pipeline opportunities beyond the lead indication
- \$95M IPO in May 2019 provides expected cash runway into 3Q, 2021, well beyond the anticipated date of Phase 3 efficacy results



Thank you